Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares
In This Article:
On September 11, 2024, Sergio Traversa, the CEO of Relmada Therapeutics Inc (NASDAQ:RLMD), purchased 140,000 shares of the company. This transaction was documented in an SEC Filing. Following this acquisition, the insider now owns a total of 384,024 shares of Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of central nervous system (CNS) diseases. The insider's recent purchase aligns with a pattern of buying activity over the past year, where Sergio Traversa has acquired a total of 240,000 shares.
The insider transaction history for Relmada Therapeutics Inc shows a trend of insider confidence, with 7 insider buys recorded over the past year and no insider sales during the same period.
Shares of Relmada Therapeutics Inc were priced at $2.82 on the day of the transaction, placing the company's market cap at $91.126 million. This valuation metric is crucial for investors considering the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow of the stock.
This insider buying activity may be of interest to current and potential investors, as it reflects the insider's perspective on the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.